How COVID-19 Affects the Brain | Neurology | JAMA Psychiatry | JAMA Network
[Skip to Navigation]
Sign In
Neuroscience and Psychiatry
March 26, 2021

How COVID-19 Affects the Brain

Author Affiliations
  • 1Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York
  • 2Department of Psychiatry, Columbia University, New York, New York
  • 3Department of Pathology and Cell Biology, Columbia University, New York, New York
  • 4Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri
  • 5Department of Neuroscience, Washington University School of Medicine in St Louis, St Louis, Missouri
  • 6Department of Pathology & Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri
JAMA Psychiatry. 2021;78(6):682-683. doi:10.1001/jamapsychiatry.2021.0500

COVID-19 has resulted in more than 120 million cases and 2.6 million deaths to date. Respiratory and gastrointestinal symptoms are accompanied by short- and long-term neuropsychiatric symptoms (NPs) and long-term brain sequelae.

Some patients present with anosmia, cognitive and attention deficits (ie, brain fog), new-onset anxiety, depression, psychosis, seizures, and even suicidal behavior.1,2 These present before, during, and after respiratory symptoms and are unrelated to respiratory insufficiency,1 suggesting independent brain damage. Follow-ups conducted in Germany and the United Kingdom found post–COVID-19 NPs in 20% to 70% of patients, even in young adults, and lasting months after respiratory symptoms resolved,1 suggesting brain involvement persists.

Entering through angiotensin-converting enzyme 2 receptors,2 SARS-CoV-2 can damage endothelial cells leading to inflammation, thrombi, and brain damage. Moreover, systemic inflammation leads to decreased monoamines and trophic factors and activation of microglia, resulting in increased glutamate and N-methyl-d-aspartate (NMDA)3 and excitotoxicity (Figure). These insults induce new-onset or re-exacerbation of preexisting NPs.

Figure.  Brain Vascular Injury, Neurotransmitter System Dysfunction, Thrombotic Events, Neuronal Damage, and Neuropsychiatric Symptoms
Brain Vascular Injury, Neurotransmitter System Dysfunction, Thrombotic Events, Neuronal Damage, and Neuropsychiatric Symptoms

A, SARS-CoV-2 invades endothelial cells via transmembrane angiotensin-converting enzyme 2 (ACE2) receptor, enabled by transmembrane protease, serine 2 (TMPRSS2). B, Cytokine elevation and microglia activation result in increased kynurenine, quinolinic acid, and glutamate, and neurotransmitter depletion. C, Coagulation cascade and elevation of von Willebrand factor (vWF) lead to thrombotic events. D, Altered neurotransmission, excitotoxicity by increased glutamate, and hypoxic injury contribute to neuronal dysfunction and loss. E, Neuropsychiatric symptoms differ depending on the Brodmann area involved. IL indicates interleukin; NMDA, N-methyl-d-aspartate; TNF, tumor necrosis factor.

Does the Virus Invade the Brain?

SARS-CoV-2 is known to penetrate the olfactory mucosa, causing loss of smell, and may enter the brain, migrating from the cribriform plate along the olfactory tract2 or through vagal or trigeminal pathways; however, definitive evidence for this is lacking. SARS-CoV-2 could pass the blood-brain barrier (BBB) because inflammatory cytokines induce BBB instability or via monocytes.4 It could reach brain tissue via circumventricular organs (CVOs), midline structures around the third and fourth ventricles, that monitor blood and cerebral spinal fluid content via fenestrated capillaries lacking the junctional proteins expressed in the BBB. Viral RNA was detected by reverse transcription–quantitative real-time polymerase chain reaction but not by in situ hybridization in medulla and cerebellum,2 located next to the area postrema, a CVO that controls emetic responses to toxins. SARS-CoV-2 protein has been found in brain vascular endothelium but not in neurons or glia.2 Thus, detected viral RNA may represent contamination by vasculature in leptomeninges and Virchow-Robin spaces. Histopathologic analysis of whole human brain showed microglial nodules and phagocytosis of neurons (neuronophagia) in brain stem and less frequently in cortex and limbic structures, associated with sparse lymphocytic infiltration, and no correlations between histopathologic findings and levels of viral messenger RNA in the same brain.5 While ageusia, nausea, and vomiting may be related to CVO and brain stem viral invasion, other short-term and long-lasting NPs are more likely due to neuroinflammation and hypoxic injury. Brain stem involvement may explain persistent autonomic abnormalities and anxiety.

Cytokines and Microglia Activation Lead to Neurotoxicity

Patients with severe COVID-19 infection have been reported to experience a severe cytokine storm, with increased serum levels of proinflammatory cytokines including interleukin (IL) 1, IL-6, IL-10, and tumor necrosis factor (TNF)-α. TNF-α can directly cross the BBB by transport (increased BBB permeability due to cytokine-induced damage)4 or CVOs. Once across the BBB, cytokines activate microglia and astrocytes.6 In addition to phagocytosing damaged cells, activated microglia secrete inflammatory mediators, including glutamate, quinolinic acid, ILs, complement proteins, and TNF-α.7 Increased quinolinic acid results in higher glutamate and upregulation of NMDA receptors, possibly inducing altered learning, memory, neuroplasticity, hallucinations, and nightmares. Excitotoxicity and neuronal loss result in region- and neurotransmitter-specific NPs.

Inflammation and NPs

Increased inflammation activates the enzyme indoleamine dioxygenase, which metabolizes tryptophan to kynurenine rather than serotonin.3 Reduced neurotransmitter release was demonstrated in patients treated with interferon alfa who exhibited increased positron emission tomography fluorodopa 18F uptake and decreased turnover in caudate and putamen, which correlated with depression and fatigue severity. Similarly, interferon- or IL-based immunotherapy can induce depression. Inflammation leads to blunted monoamine neurotransmission, anhedonia, negative cognitive, psychomotor and neurovegetative symptoms, depression, and suicidal behavior, which poorly respond to conventional antidepressants.3 In individuals who attempt suicide and have major depressive disorder, studies found elevated plasma kynurenine, high IL-1 and IL-6 levels in blood, cerebral spinal fluid, and brain, and increased serum C-reactive protein correlating with brain glutamate levels. TNF-α and IL-6 levels may predict negative and depressive symptoms in people at risk of psychosis, and higher IL-6 correlates with smaller hippocampus volume. Elevated IL-1β signaling decreases hippocampal neurogenesis and increases apoptosis in mammals. Suicide decedents with major depressive disorder have increased proinflammatory and decreased neurogenesis markers in postmortem hippocampus,8 together with smaller dentate gyrus, fewer granule neurons, and neural progenitor cells.9 Therefore, neuroinflammation may contribute to the pathogenesis of NPs reducing neurotransmitters and neurotrophins and increasing excitotoxicity.3

Interplay of Inflammation and Coagulation

Virus entrance into endothelial cells of brain vasculature activates neutrophils, macrophages, thrombin production, and complement pathways, promoting microthrombi deposition.2 COVID-19 brain damage shows macro– and micro–hypoxic/ischemic injury and infarcts at autopsy.5 Moreover, the complement cascade mediates synaptic pruning by microglia following viral infections.7 Therefore, NPs of COVID-19 could result from microstrokes and neuronal damage, and symptoms consequently differ depending on the brain region involved. Mechanisms of COVID-19 brain damage may resemble those involved in traumatic brain injury, where a combination of proinflammatory status and microvascular injury resulting in neuronal loss have been implicated in the pathogenesis of suicidal behavior.10 Conversely, a successful clinical outcome would result from an initial immune response involving toll receptors and blunted nonpriming or low-priming delayed inflammation.

Understanding cellular and molecular aspects of COVID-19 brain damage could direct interventions to reduce long-term NPs. Interventions may involve antagonists of cytokines (etanercept, infliximab), NMDA receptor (ketamine), TNF-α and anti-inflammatory pathways (aspirin, celecoxib), and kynurenine pathway modulators (minocycline).3 Mitigating long-term post–COVID-19 cognitive, emotional, and behavioral sequelae would decrease disease burden. COVID-19 neuropathology may serve as a model for deciphering neurodegenerative processes related to neuroinflammation in other brain diseases and developing new treatment strategies.

Back to top
Article Information

Corresponding Author: Maura Boldrini, MD, PhD, Department of Psychiatry, New York State Psychiatric Institute, Columbia University Irving Medical Center, 1051 Riverside Dr, Unit 42, New York, NY 10032 (

Published Online: March 26, 2021. doi:10.1001/jamapsychiatry.2021.0500

Conflict of Interest Disclosures: Dr Boldrini is supported by the National Institutes of Health, the American Foundation for Suicide Prevention, Dr Brigitt Rok Foundation, and the Morris Stroud III Center for Study of Quality of Life in Health and Aging at Columbia University. Drs Canoll and Klein are supported by the National Institutes of Health.

Additional Contributions: We thank Helen Blair Simpson, MD, PhD (New York State Psychiatric Institute and Columbia University), for reviewing a draft of this work. Dr Simpson was not compensated.

Woo  MS, Malsy  J, Pöttgen  J,  et al.  Frequent neurocognitive deficits after recovery from mild COVID-19.   Brain Commun. 2020;2(2):fcaa205. doi:10.1093/braincomms/fcaa205Google Scholar
Meinhardt  J, Radke  J, Dittmayer  C,  et al.  Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19.   Nat Neurosci. 2021;24(2):168-175.PubMedGoogle ScholarCrossref
Roman  M, Irwin  MR.  Novel neuroimmunologic therapeutics in depression.   Brain Behav Immun. 2020;83:7-21. doi:10.1016/j.bbi.2019.09.016PubMedGoogle ScholarCrossref
Daniels  BP, Holman  DW, Cruz-Orengo  L, Jujjavarapu  H, Durrant  DM, Klein  RS.  Viral pathogen-associated molecular patterns regulate blood-brain barrier integrity via competing innate cytokine signals.   mBio. 2014;5(5):e01476-e14. doi:10.1128/mBio.01476-14PubMedGoogle ScholarCrossref
Al-Dalahmah  O, Thakur  KT, Nordvig  AS,  et al.  Neuronophagia and microglial nodules in a SARS-CoV-2 patient with cerebellar hemorrhage.   Acta Neuropathol Commun. 2020;8(1):147. doi:10.1186/s40478-020-01024-2PubMedGoogle ScholarCrossref
Liddelow  SA, Guttenplan  KA, Clarke  LE,  et al.  Neurotoxic reactive astrocytes are induced by activated microglia.   Nature. 2017;541(7638):481-487. doi:10.1038/nature21029PubMedGoogle ScholarCrossref
Vasek  MJ, Garber  C, Dorsey  D,  et al.  A complement-microglial axis drives synapse loss during virus-induced memory impairment.   Nature. 2016;534(7608):538-543. doi:10.1038/nature18283PubMedGoogle ScholarCrossref
Mahajan  GJ, Vallender  EJ, Garrett  MR,  et al.  Altered neuro-inflammatory gene expression in hippocampus in major depressive disorder.   Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:177-186. doi:10.1016/j.pnpbp.2017.11.017PubMedGoogle ScholarCrossref
Boldrini  M, Galfalvy  H, Dwork  AJ,  et al.  Resilience is associated with larger dentate gyrus, while suicide decedents with major depressive disorder have fewer granule neurons.   Biol Psychiatry. 2019;85(10):850-862. doi:10.1016/j.biopsych.2018.12.022PubMedGoogle ScholarCrossref
Wadhawan  A, Stiller  JW, Potocki  E,  et al.  Traumatic brain injury and suicidal behavior.   J Alzheimers Dis. 2019;68(4):1339-1370. doi:10.3233/JAD-181055PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    Response to: How COVID-19 affects the brain
    Paolo Manfredi, MD | Relmada Therapeutics, Inc.
    We read with interest Dr. Boldrini's article on the potential role of quinolinic acid in the pathophysiology of neuropsychiatric complications of COVID-19 via hyperactivation of N-methyl-D-aspartate receptors (NMDAR).1 Uncompetitive NMDAR channel blockers, such as ketamine and esketamine, are emerging as a new drug class with rapid onset of efficacy for major depressive disorder (MDD). However, both ketamine and esketamine cause dissociative effects in a high percentage of patients at therapeutic doses. Esmethadone, the opioid-inactive d-isomer of racemic methadone2 is a low affinity and low potency NMDAR channel blocker effective in murine models of depressive-like behavior3 and with robust, rapid, and sustained therapeutic effects in patients with MDD at once-daily 25 and 50 mg oral doses (Fava et al: manuscript submitted). Esmethadone is currently in Phase 3 clinical development for MDD (Relmada Therapeutics). Esmethadone has similar "trapping" properties at NMDARs compared to ketamine, but lower potency (Bettini et al: manuscript in preparation) and is devoid of psychotomimetic effects or other cognitive side effects.4 In support of the therapeutic role hypothesized by Boldrini for NMDAR channel blockers for COVID-19 neuropsychiatric symptoms,1 esmethadone reduces Ca+ influx induced by glutamate and quinolinic acid (Bettini et al: manuscript in preparation). Furthermore, some of the lung, heart, kidney, and coagulation complications of COVID-19 also could be related to NMDAR hyper-activation by endogenous inflammatory mediators,5 and thus, could be mitigated by NMDAR channel blockers. Because of the hypothesized mechanism of action, the strong signal for efficacy for patients with MDD, and the favorable safety, tolerability, and pharmacokinetic profile, esmethadone should be tested in controlled trials for prevention and treatment of complications secondary to COVID-19. In parallel, we will explore with the Food and Drug Administration the possibility of meeting the threshold for emergency use authorization (EUA) in the United States.

    1. Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA Psychiatry. 2021 Mar 26. doi: 10.1001/jamapsychiatry.2021.0500.
    2. Drug Enforcement Administration (DEA). Diversion Control Division. Drug & Chemical Evaluation Section. Methadone. July 2019.
    3. Fogaça MV, Fukumoto K, Franklin T, Liu RJ, Duman CH, Vitolo OV, Duman RS. N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology. 2019;44(13):2230-2238.
    4. Bernstein G, Davis K, Mills C, Wang L, McDonnell M, Oldenhof J, Inturrisi C, Manfredi PL, Vitolo OV. Characterization of the Safety and Pharmacokinetic Profile of d-methadone, a novel n-methyl-d-aspartate receptor antagonist in healthy, opioid-naive subjects: Results of two phase 1 studies. J Clin Psychopharmacol. 2019;39(3):226-237.
    5. Du J, Li XH, Li YJ. Glutamate in peripheral organs: Biology and pharmacology. Eur J Pharmacol. 2016;784:42-8.


    Stephen Stahl, MD, PhD
    University of California, San Diego and Neuroscience Institute, San Diego, CA

    Ezio Bettini, PhD
    Aptuit an Evotec Company, Verona, Italy

    Paolo L Manfredi, MD
    Relmada Therapeutics, Inc., New York, NY
    CONFLICT OF INTEREST: Drs. Stahl and Manfredi are paid consultants for Relmada Therapeutics. Evotec conducts studies sponsored by Relmada Therapeutics